Could a lung drug fix blood vessel damage in rare artery disease?
NCT ID NCT07325357
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding pirfenidone, a drug used for lung and liver scarring, to standard treatment can improve blood vessel damage in people with Takayasu arteritis. About 92 adults aged 18-60 will receive either pirfenidone or a placebo for 6 months. The goal is to see if the drug can reduce vessel wall thickening and help patients feel better.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TAKAYASU ARTERITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Rare artery disease linked to higher heart attack and stroke risk
- New Total-Body PET scanner could revolutionize vasculitis diagnosis
- 5,000 patients to help unlock secrets of inflammatory heart disease
- New hope for rare artery disease? small trial tests upadacitinib
- Hope for takayasu patients: study tests stopping biologic drugs after years of remission